Penumbra, Inc. is a healthcare company.
Penumbra, Inc. (PEN) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 16:14 ET. Consensus EPS estimate is $1.20.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $1.16 | $0.88 | -24.1% | $390.05M |
| 2026-05-06 | FY2026 Q1 | $1.04 | $0.83 | -20.2% | $374.76M |
| 2026-02-25 | FY2025 Q4 | $1.11 | $1.21 | +9.0% | $385.38M |
| 2025-11-05 | FY2025 Q3 | $0.93 | $1.17 | +25.9% | $354.69M |
| 2025-07-29 | FY2025 Q2 | $0.81 | $1.17 | +44.4% | $339.45M |
| 2025-04-23 | FY2025 Q1 | $0.66 | $1.02 | +54.5% | $324.14M |
| 2025-02-18 | FY2024 Q4 | $0.88 | $0.88 | +0.0% | $315.52M |
| 2024-10-30 | FY2024 Q3 | $0.69 | $0.76 | +10.1% | $301.04M |
PEN has beaten consensus EPS in 6 of its last 8 reported quarters.
Highlights from PEN's Jul 30 report: EPS of $0.88 — a sharp miss vs the $1.16 estimate (-24%); revenue of $390M — in line with the $390M consensus. Focus now shifts to thrombectomy adoption and stroke.
See PEN on the live calendar →